Intravascular Lymphoma in the CNS: Options for Treatment

Area of Science:

• Neurology
• Oncology
• Pharmacology

Background:

• Intravascular lymphoma (IVL) is a rare extranodal non-Hodgkin lymphoma.
• Central nervous system (CNS) involvement in IVL presents significant diagnostic and therapeutic challenges.
• Effective treatment strategies for CNS IVL are crucial for improving patient outcomes.

Purpose of the Study:

• To review current therapeutic manipulations and interventions for intravascular lymphoma in the CNS.
• To analyze and compare various treatment avenues for CNS IVL.
• To highlight the efficacy of combinational intrathecal chemotherapy with rituximab.

Main Methods:

• Review of recent findings on therapeutic interventions for CNS IVL.
• Analysis of treatment outcomes including disease remission and duration.
• Comparison of different chemotherapy regimens and supportive therapies.

Main Results:

• Patients achieved disease remission for up to 2 years following R-CHOP and intrathecal therapy (MTX, cytarabine, prednisolone).
• Intrathecal administration of chemotherapy bypasses the blood-brain barrier, allowing lower, less toxic doses.
• Unfractionated heparin use during therapy may be associated with improved outcomes.

Conclusions:

• Combinational intrathecal methotrexate-based chemotherapy with rituximab is an effective current treatment for CNS IVL.
• Intrathecal chemotherapy is beneficial for both treatment and prophylaxis in CNS IVL patients.
• Minimizing systemic toxicity through intrathecal administration is a key advantage.